| Identification and characterization of metabolically benign obesity in humans N Stefan, K Kantartzis, J Machann, F Schick, C Thamer, K Rittig, ... Archives of internal medicine 168 (15), 1609-1616, 2008 | 1359 | 2008 |
| Causes and metabolic consequences of fatty liver N Stefan, K Kantartzis, HU Häring Endocrine reviews 29 (7), 939-960, 2008 | 750 | 2008 |
| Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene K Kantartzis, A Peter, F Machicao, J Machann, S Wagner, I Königsrainer, ... Diabetes 58 (11), 2616-2623, 2009 | 351 | 2009 |
| High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease K Kantartzis, C Thamer, A Peter, J Machann, F Schick, C Schraml, ... Gut 58 (9), 1281-1288, 2009 | 337 | 2009 |
| Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial S Kahl, S Gancheva, K Straßburger, C Herder, J Machann, H Katsuyama, ... Diabetes care 43 (2), 298-305, 2020 | 311 | 2020 |
| Polymorphisms within novel risk loci for type 2 diabetes determine β-cell function H Staiger, F Machicao, N Stefan, O Tschritter, C Thamer, K Kantartzis, ... PloS one 2 (9), e832, 2007 | 211 | 2007 |
| Relationships of circulating sex hormone–binding globulin with metabolic traits in humans A Peter, K Kantartzis, J Machann, F Schick, H Staiger, F Machicao, ... diabetes 59 (12), 3167-3173, 2010 | 196 | 2010 |
| Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans N Stefan, K Kantartzis, N Celebi, H Staiger, J Machann, F Schick, ... Diabetes Care 33 (2), 405-407, 2010 | 194 | 2010 |
| Effects of a lifestyle intervention in metabolically benign and malign obesity K Kantartzis, J Machann, F Schick, K Rittig, F Machicao, A Fritsche, ... Diabetologia 54 (4), 864-868, 2011 | 185 | 2011 |
| Effects of a lifestyle intervention in metabolically benign and malign obesity K Kantartzis, J Machann, F Schick, C Thamer, K Rittig, B Balletshofer, ... DIABETES 59, A485-A485, 2010 | 185 | 2010 |
| The impact of liver fat vs visceral fat in determining categories of prediabetes K Kantartzis, J Machann, F Schick, A Fritsche, HU Häring, N Stefan Diabetologia 53 (5), 882-889, 2010 | 177 | 2010 |
| High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention C Thamer, J Machann, N Stefan, M Haap, S Schäfer, S Brenner, ... Obesity 15 (2), 531-538, 2007 | 175 | 2007 |
| Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine β-cell function H Staiger, F Machicao, SA Schäfer, K Kirchhoff, K Kantartzis, M Guthoff, ... PLoS One 3 (12), e3962, 2008 | 163 | 2008 |
| Lifestyle intervention in individuals with normal versus impaired glucose tolerance S Schäfer, K Kantartzis, J Machann, C Venter, A Niess, F Schick, ... European journal of clinical investigation 37 (7), 535-543, 2007 | 148 | 2007 |
| Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes J Machann, C Thamer, N Stefan, NF Schwenzer, K Kantartzis, HU Häring, ... Radiology 257 (2), 353-363, 2010 | 145 | 2010 |
| The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity K Kantartzis, K Rittig, B Balletshofer, J Machann, F Schick, K Porubska, ... Clinical chemistry 52 (10), 1934-1942, 2006 | 136 | 2006 |
| Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial N Stefan, M Ramsauer, P Jordan, B Nowotny, K Kantartzis, J Machann, ... The Lancet Diabetes & Endocrinology 2 (5), 406-416, 2014 | 132 | 2014 |
| Circulating lysophosphatidylcholines are markers of a metabolically benign nonalcoholic fatty liver R Lehmann, H Franken, S Dammeier, L Rosenbaum, K Kantartzis, ... Diabetes care 36 (8), 2331-2338, 2013 | 127 | 2013 |
| Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion K Müssig, H Staiger, F Machicao, K Kirchhoff, M Guthoff, SA Schäfer, ... Diabetes 58 (7), 1715-1720, 2009 | 121 | 2009 |
| New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms SA Schäfer, F Machicao, A Fritsche, HU Häring, K Kantartzis Diabetes research and clinical practice 93, S9-S24, 2011 | 119 | 2011 |